Amgen Inc.

NasdaqGS:AMGN Lagerbericht

Marktkapitalisierung: US$150.5b

Amgen Management

Management Kriterienprüfungen 3/4

Amgen CEO ist Bob Bradway , ernannt in May 2010, hat eine Amtszeit von 14.5 Jahren. Die jährliche Gesamtvergütung beträgt $22.64M , bestehend aus 7.9% Gehalt und 92.1% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.12% der Aktien des Unternehmens, im Wert von $175.94M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 4.8 Jahre bzw. 7.9 Jahre.

Wichtige Informationen

Bob Bradway

Geschäftsführender

US$22.6m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts7.9%
Amtszeit als Geschäftsführer14.5yrs
Eigentum des Geschäftsführers0.1%
Durchschnittliche Amtszeit des Managements4.8yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder7.9yrs

Jüngste Management Updates

Recent updates

Amgen Sells Off: Keep Calm And Buy The Dip

Nov 18

Amgen's (NASDAQ:AMGN) Problems Go Beyond Weak Profit

Nov 08
Amgen's (NASDAQ:AMGN) Problems Go Beyond Weak Profit

Amgen: A Biotech Giant Offering Value And Growth In A Frothy Market

Nov 03

Amgen Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year

Nov 02
Amgen Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year

Amgen Q3 Earnings Review: So Many Questions, But MariTide Data Top Of The List

Oct 25

Amgen: Pipeline Updates, Uplizna Performs And Rocatinlimab Underwhelms

Sep 26

Amgen: Growth Is Still A Better Choice

Aug 28

Amgen Inc. Just Missed EPS By 46%: Here's What Analysts Think Will Happen Next

Aug 09
Amgen Inc. Just Missed EPS By 46%: Here's What Analysts Think Will Happen Next

Amgen: Shows Why Dividend Investing Is Getting Tougher

Aug 07

Amgen (NASDAQ:AMGN) Takes On Some Risk With Its Use Of Debt

Jul 26
Amgen (NASDAQ:AMGN) Takes On Some Risk With Its Use Of Debt

The Price Is Right For Amgen Inc. (NASDAQ:AMGN)

Jul 11
The Price Is Right For Amgen Inc. (NASDAQ:AMGN)

Amgen: An Emerging GLP-1 Play, Modest Mid-Teens P/E With Strong Momentum

Jul 05

Amgen: You Haven't Seen Anything Yet

Jun 17

Amgen Is A Fantastic Dividend Growth Stock With A Weight-Loss Wild Card

Jun 04

Amgen Stock: Poised To Break Out (Technical Analysis)

May 21

Is Amgen Inc. (NASDAQ:AMGN) Trading At A 41% Discount?

May 04
Is Amgen Inc. (NASDAQ:AMGN) Trading At A 41% Discount?

Amgen Stock: Recent Weakness Is Not A Buying Opportunity Yet

May 01

Amgen: The Giant With An Impressive Pipeline

Apr 15

Is Amgen (NASDAQ:AMGN) Using Too Much Debt?

Apr 01
Is Amgen (NASDAQ:AMGN) Using Too Much Debt?

Move Over Eli Lilly: Amgen Could Be The Next Obesity Wonder Stock

Mar 31

Amgen Will Benefit From Increased Medical Spending

Mar 12

Amgen: A Good Dividend Growth Stock For The Watch List

Mar 04

Amgen's (NASDAQ:AMGN) Shareholders May Want To Dig Deeper Than Statutory Profit

Feb 21
Amgen's (NASDAQ:AMGN) Shareholders May Want To Dig Deeper Than Statutory Profit

Pinning Down Amgen Inc.'s (NASDAQ:AMGN) P/E Is Difficult Right Now

Feb 16
Pinning Down Amgen Inc.'s (NASDAQ:AMGN) P/E Is Difficult Right Now

Amgen: Weight Loss Drug Candidate Debate A Red Herring - Buying The Dip Advisable

Feb 08

Amgen: Accelerating The Business And Dividend Growth

Jan 29

Is Amgen Inc. (NASDAQ:AMGN) Trading At A 44% Discount?

Jan 29
Is Amgen Inc. (NASDAQ:AMGN) Trading At A 44% Discount?

Up 40%, 3%-Yielding Amgen Is Still One Of My Favorite Healthcare Stocks

Jan 22

Is Amgen (NASDAQ:AMGN) A Risky Investment?

Dec 28
Is Amgen (NASDAQ:AMGN) A Risky Investment?

Here's Why Amgen (NASDAQ:AMGN) Has Caught The Eye Of Investors

Dec 13
Here's Why Amgen (NASDAQ:AMGN) Has Caught The Eye Of Investors

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Bob Bradway im Vergleich zu den Einnahmen von Amgen verändert?
DatumGesamtvergütungGehaltUnternehmensgewinne
Sep 30 2024n/an/a

US$4b

Jun 30 2024n/an/a

US$3b

Mar 31 2024n/an/a

US$4b

Dec 31 2023US$23mUS$2m

US$7b

Sep 30 2023n/an/a

US$8b

Jun 30 2023n/an/a

US$8b

Mar 31 2023n/an/a

US$8b

Dec 31 2022US$21mUS$2m

US$7b

Sep 30 2022n/an/a

US$7b

Jun 30 2022n/an/a

US$7b

Mar 31 2022n/an/a

US$6b

Dec 31 2021US$22mUS$2m

US$6b

Sep 30 2021n/an/a

US$6b

Jun 30 2021n/an/a

US$6b

Mar 31 2021n/an/a

US$7b

Dec 31 2020US$20mUS$2m

US$7b

Sep 30 2020n/an/a

US$7b

Jun 30 2020n/an/a

US$7b

Mar 31 2020n/an/a

US$8b

Dec 31 2019US$20mUS$2m

US$8b

Sep 30 2019n/an/a

US$8b

Jun 30 2019n/an/a

US$8b

Mar 31 2019n/an/a

US$8b

Dec 31 2018US$19mUS$2m

US$8b

Sep 30 2018n/an/a

US$2b

Jun 30 2018n/an/a

US$2b

Mar 31 2018n/an/a

US$2b

Dec 31 2017US$17mUS$2m

US$2b

Vergütung im Vergleich zum Markt: BobDie Gesamtvergütung ($USD22.64M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD12.73M).

Entschädigung vs. Einkommen: BobDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

Bob Bradway (61 yo)

14.5yrs

Amtszeit

US$22,643,650

Vergütung

Mr. Robert A. Bradway, also known as Bob, has been the Chief Executive Officer of Amgen Inc. since May 23, 2012 and has been its President since May 2010. Mr. Bradway is responsible for the Amgen's global...

Führungsteam

NamePositionAmtszeitVergütungEigentümerschaft
Robert Bradway
Chairman14.5yrsUS$22.64m0.12%
$ 175.9m
Peter Griffith
Executive VP & CFO4.8yrsUS$7.57m0.0046%
$ 6.9m
Esteban Santos
Executive Vice President of Operations8.3yrsUS$7.21m0.011%
$ 17.2m
David Reese
Executive VP & CTOless than a yearUS$7.90m0.0094%
$ 14.1m
Murdo Gordon
Executive Vice President of Global Commercial Operations6.2yrsUS$8.24m0.0075%
$ 11.2m
Matthew Busch
Chief Accounting Officer & VP of Finance1.3yrskeine Daten0.00062%
$ 933.0k
James Bradner
Executive VP of Research & Development and Chief Scientific Officerless than a yearkeine Datenkeine Daten
Justin Claeys
Vice President of Investor Relationsno datakeine Datenkeine Daten
Jonathan Graham
Executive VP9.3yrsUS$7.24m0.0046%
$ 7.0m
Nancy Grygiel
Senior VP of Worldwide Compliance & Business Ethics and Chief Compliance Officer4.8yrskeine Daten0.0013%
$ 2.0m
Kave Niksefat
Senior Vice President of Global Marketing & Accessless than a yearkeine Datenkeine Daten
Derek Miller
Senior Vice President of Human Resources2.8yrskeine Daten0.0012%
$ 1.7m

4.8yrs

Durchschnittliche Betriebszugehörigkeit

56.5yo

Durchschnittliches Alter

Erfahrenes Management: AMGNDas Führungsteam des Unternehmens gilt als erfahren (4.8 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

NamePositionAmtszeitVergütungEigentümerschaft
Robert Bradway
Chairman13.1yrsUS$22.64m0.12%
$ 175.9m
Robert Eckert
Lead Independent Director11.9yrsUS$419.92k0.0013%
$ 2.0m
David Baltimore
Co-Chair of Scientific Advisory Boardno dataUS$292.01kkeine Daten
Charles Sigal
Co-Chair of the Scientific Advisory Boardno datakeine Datenkeine Daten
Amy Miles
Independent Director4.3yrsUS$359.92k0.000080%
$ 120.4k
Charles Holley
Independent Director7.8yrsUS$369.92k0.00023%
$ 346.1k
Greg Garland
Independent Director11.1yrsUS$379.92k0.0023%
$ 3.5m
Ellen Kullman
Independent Director8.1yrsUS$360.29k0.000080%
$ 120.4k
Brian Druker
Independent Director6.5yrsUS$359.92k0.00015%
$ 225.7k
Tyler Jacks
Independent Director12.5yrsUS$339.92k0.00051%
$ 767.5k
Wanda Austin
Independent Director6.9yrsUS$359.92k0.0012%
$ 1.8m
S. Ishrak
Independent Director3.3yrsUS$366.47k0.00017%
$ 255.8k

7.9yrs

Durchschnittliche Betriebszugehörigkeit

68yo

Durchschnittliches Alter

Erfahrener Vorstand: AMGNDie Vorstandsmitglieder gelten als erfahren (7.9 Jahre durchschnittliche Amtszeit).